Given that PARP inhibitors may diminish or inhibit BRCA1 expression, combining olaparib with gefitinib could potentially enhance outcomes for patients with advanced EGFR-mutant NSCLC. The gene discussed is PARP1; the disease is non-small cell lung carcinoma.